We develop immune therapies that support the treatment and prevention of infectious disease and cancer

We develop immune therapies that directly stimulate a powerful immune response in the liver

Our lead programme is targeting a cure for the 250 million patients infected with chronic hepatitis B

Hepatitis B virus infection

Despite the availability of preventative vaccines, 2 billion people worldwide have been infected with hepatitis B virus (HBV). Over 250 million of those infected progress to chronic HBV infection and become susceptible to life threatening liver disease.  Avalia’s therapy aims to provide a necessary cure for these individuals.

Read More
>

Pipeline

Avalia’s immune therapies are designed to target the liver and spleen to modulate a more potent and targeted immune response against certain viruses and cancers. This is achieved by activating a special family of immune cells called natural killer T cells.

Read More
>

News

Avalia presents latest research at the Neoantigen conference

Avalia is attending the European Neoantigen Summit in Amsterdam, 24-26 April, presenting a poster introducing its powerful vaccine platform.  Please contact us directly if you would like to arrange a time to meet.

Read More
>

Meet with Avalia at BIO International Conference this June 2017

Please contact us directly to arrange a time to meet or use the BIO One-on-One partnering portal to meet during the conference.

Read More
>

Five-year research partnership

Avalia's research partner, the Ferrier Research Institute at Victoria University of Wellington continues to pioneer new ground with Avalia's NKT cell agonist vaccines.

Read More
>

Meet with Avalia’s CEO at Biotech Showcase in San Francisco, January 9-11, 2017

Please contact us directly to arrange a time to meet.

Read More
>

NZ bioscience celebrates its innovators

At the Annual NZ Bio award dinner, Wednesday night 23rd September, Dr Shivali Gulab was announced the Young Bioscientist of the Year.

Read More
>